Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors- An analysis of 2765 patients from neoadjuvant clinical trials

Erstveröffentlichung
2021Authors
Villegas, Sonia L.
Nekljudova, Valentina
Pfarr, Nicole
Engel, Jutta
Untch, Michael
Wissenschaftlicher Artikel
Published in
European Journal of Cancer ; 148 (2021). - S. 159-170. - ISSN 0959-8049. - eISSN 1879-0852
Link to publication
https://dx.doi.org/10.1016/j.ejca.2021.02.020Institutions
UKU. Klinik für Frauenheilkunde und GeburtshilfeSubject headings
[Free subject headings]: Breast neoplasms | Breast cancer | Mammary cancer | ER-negative PR-negative HER2-negative breast cancer | Triple-negative breast cancer | Oestrogen receptors | Progesterone receptors | Hormone-dependent neoplasms | Neoadjuvant therapy | Cancer biomarkers | INTERNATIONAL EXPERT CONSENSUS | LIGAND-BINDING ASSAY | PREDICTING RESPONSE | ESTROGEN-RECEPTORS | AMERICAN SOCIETY | ADJUVANT BREAST | ER | CHEMOTHERAPY | IMMUNOHISTOCHEMISTRY | ONCOLOGY/COLLEGE[DDC subject group]: DDC 610 / Medicine & health
Metadata
Show full item recordThis could also interest you:
-
Breast cancer risk inBRCA1/2mutation carriers and noncarriers under prospective intensified surveillance
Engel, Christoph et al. (2020)Wissenschaftlicher Artikel
-
Association of death receptor 4 variant (683A > C) with ovarian cancer risk in BRCA1 mutation carriers
Dick, Michelle G. et al. (2012)Wissenschaftlicher Artikel
-
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients
Moebus, Volker et al. (2017)Wissenschaftlicher Artikel